Frontier to PiT

Output Explorer

Every prompt in the paper, and what each model wrote back.

Return exactly ten single-sentence facts as JSON. Quality was judged pairwise; here you see the raw outputs and whether the JSON parsed.

13 of 1,000 prompts

ASPN · Q1 20262026-05-07FCX · Q1 20262026-04-23RAMP · Q2 20262025-11-05PFSI · Q2 20252025-07-22CSGS · Q2 20252025-08-06PCT · Q2 20252025-08-07HCA · Q3 20252025-10-24KMPR · Q3 20252025-11-05GPOR · Q4 20252026-02-25V · Q2 20262026-04-28LFCR · Q4 20252025-08-07AYI · Q1 20262026-01-08TENB · Q2 20252025-07-30

Nearby prompts. All 1,000 Earnings calls prompts

PromptHCA· Q3 2025 · call on2025-10-24· transcript 50,447 characters
Analyze the following earnings call transcript and extract the 10 most investor-relevant facts.

Each fact must:
- Be drawn only from the transcript (do not use any outside information).
- Be a single sentence capturing a specific, quantified insight relevant to investors.
- Avoid regurgitating the transcript verbatim; instead, synthesize and distill the information into investor-relevant facts.

Return only a JSON object with this exact structure (no markdown fences, no commentary):
{"facts": ["<fact 1>", "<fact 2>", ..., "<fact 10>"]}

The list must contain exactly 10 facts.

Transcript:
<transcript>
transcript redacted — the source calls are not publicly licensed
</transcript>
System prompt · identical for every setup
You are a financial analyst. You extract the most investor-relevant facts from earnings call transcripts to help investors anticipate the stock's reaction to the call.
Reference

No reference summary is published. Quality was judged pairwise by a separate model and is reported in aggregate on the main page.

Models
4 of 4 columns · click a model to add or remove it

Ours

10 facts · valid JSON
  1. HCA raised its 2025 full-year guidance to project revenues between $75 billion and $76.5 billion and diluted earnings per share between $27 and $28.
  2. The company reported 42% year-over-year growth in adjusted diluted earnings per share driven by revenue increases of 9.6% and disciplined operational management.
  3. Same-facility equivalent admissions increased by 2.4% in Q3 2025, while total commercial equivalent admissions grew by 3.7% with exchanges specifically up 8%.
  4. Medicaid state supplemental payment programs contributed approximately $240 million to adjusted EBITDA in Q3 2025, accounting for roughly half of the net revenue per admission growth.
  5. Management expects the full-year 2025 net benefit from supplemental payments to range between $250 million and $350 million favorable compared to 2024, excluding pending grandfathered applications from CMS.
  6. Contract labor costs represented only 4.2% of total labor costs in Q3 and remained flat year-over-year, helping to drive improved adjusted EBITDA margins.
  7. The company generated $4.4 billion in operating cash flow during the quarter, deploying $2.5 billion toward share repurchases and $1.3 billion toward federal income tax deferrals.
  8. Hurricane-impacted markets are currently tracking flat year-to-year in EBITDA, but the company anticipates recovering approximately $100 million of the 2024 headwind specifically in Q4 2025.
  9. Professional fees increased 11% year-over-year in Q3, running hotter than average inflation primarily due to anesthesia and radiology costs related to the recent Valesco acquisition integration.
  10. Management forecasts long-term volume growth to remain within its 2% to 3% target range despite uncertainty surrounding federal premium tax credits and exchange coverage.
1,842 characters432 tokens

Aux 2015

Invalid JSONshown as written

Based on the transcript, here are the 10 most investor-relevant facts extracted from HCA Healthcare's Q3 2025 earnings call:

  1. Revenue Growth & Payer Mix:

    • Revenue increased 9.6% over Q3 2024, driven by broad-based volume growth, improved payer mix, and Medicaid supplemental payments.
    • Same-facility total commercial equivalent admissions increased 3.7%, while Medicare and Medicaid ER visits combined increased 4.1%.
    • Medicaid and self-pay ER visits declined 6% and 1% respectively.

  2. Adjusted EBITDA & Margin:

    • Adjusted EBITDA increased 11.5% to $1.3 billion, driven by strong labor and supply costs.
    • Adjusted EBITDA margin improved to 12.5% from 11.8% in Q3 2024.
    • Contract labor costs were flat, representing 4.2% of total labor cost.

  3. Payer Mix & Medicaid State Supplemental Payments:

    • Same-facility total commercial equivalent admissions increased 3.7%, while Medicare and Medicaid ER visits combined increased 4.1%.
    • Medicaid and self-pay ER visits declined 6% and 1% respectively.
    • Tennessee program payments and the Kansas and Texas grandfathered applications increased $240 million in net benefit.

  4. Volume & Patient Volume:

    • Same-facility total surgical volume increased 1.4% over Q3 2024.
    • Same-facility ER visits increased 1.3% over Q3 2024.
    • Commercial and Medicare ER visits combined increased 4.1% over Q3 2024.
    • Medicaid and self-pay ER visits declined 6% over Q3 2024.

  5. Labor & Supplies:

    • Contract labor costs were flat at 4.2% of total labor cost.
    • Supplies cost increased 11.5% over Q3 2024.
    • Supplies represented 11.5% of total other operating expenses.

  6. Capital Allocation:

    • Cash flow from operations was $4.4 billion, with $1.3 billion in capital expenditures, $2.5 billion in share repurchases, and $166 million in dividends.
    • Debt-to-adjusted EBITDA ratio remained in the lower half of guidance range.

  7. Hurricane Impact:

    • Hurricane-impacted markets produced $100 million in adjusted EBITDA growth and full year 2025 over 2024.
    • The $100 million increase in net benefit from state supplemental payments was driven by Tennessee and Texas grandfathered applications.

  8. 2025 Guidance:

    • Revenue range: $75–$76.5 billion
    • Net income range: $6.50–$6.72 billion
    • Adjusted EBITDA range: $15.25–$15.65 billion
    • Diluted earnings per share range: $27–$28
    • Capital spending range: $5 billion
    • Supplemental payment full year net benefit range: $250–$350 million (favorable)
    • Full year 2025 guidance update does not include impact from any additional state supplemental payment applications.

  9. 2026 Guidance:

    • Revenue range: $75–$76.5 billion
    • Net income range: $6.50–$6.72 billion
    • Adjusted EBITDA range: $15.25–$15.65 billion
    • Diluted earnings per share range: $27–$28
    • Capital spending range: $5 billion
    • Full year 2026 guidance update does not include any potential impact from any additional state supplemental payment applications.

  10. Hurricane Impact:

  • Hurricane-impacted markets produced $100 million in adjusted EBITDA growth and full year 2025 over 2024.
  • The $100 million increase in net benefit from state supplemental payments was driven by Tennessee and Texas grandfathered applications.

These facts provide a comprehensive view of HCA's financial performance, operational performance, and strategic initiatives, all derived from the Q3 2025 earnings call transcript.

3,498 charactersfirst of 2 attempts993 tokens

PiT-FT 2015

Invalid JSONshown as written
<|assistant|>
<|assistant|>
<|assistant|>

The same 14-character fragment repeats 292 times until the token limit. Showing the first three.

4,099 charactersfirst of 2 attempts2,048 tokens

ChronoGPT 2015

Invalid JSONshown as written

### Final Answer:
26 charactersfirst of 2 attempts11 tokens